Sanofi to acquire Ablynx for €3.9bn

Biopharmaceutical company Sanofi has revealed plans to acquire biotech firm Ablynx for approximately €3.9 billion ($4.8 billion).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Seattle Genetics to acquire biotech company for $614m

2 February 2018 Seattle Genetics has announced that it will acquire biotech company Cascadian Therapeutics for approximately $614 million.

Europe

Sanofi in talks to sell generics unit for €1.9bn

19 April 2018 France-based Sanofi has confirmed it is in negotiations to sell its European generics business Zentiva for €1.9 billion ($2.4 billion) to private equity firm Advent International.

Americas

Allele Biotech partners with Scientist.com to develop nanoantibodies

5 December 2018 US-based Allele Biotechnology & Pharmaceuticals, a preclinical-stage biopharmaceutical company, has teamed up with a scientific e-commerce marketplace network in efforts to develop nanoantibodies for therapeutic applications.

More on this story

Americas

Seattle Genetics to acquire biotech company for $614m

2 February 2018 Seattle Genetics has announced that it will acquire biotech company Cascadian Therapeutics for approximately $614 million.

Europe

Sanofi in talks to sell generics unit for €1.9bn

19 April 2018 France-based Sanofi has confirmed it is in negotiations to sell its European generics business Zentiva for €1.9 billion ($2.4 billion) to private equity firm Advent International.

Americas

Allele Biotech partners with Scientist.com to develop nanoantibodies

More on this story

Americas

Seattle Genetics to acquire biotech company for $614m

2 February 2018 Seattle Genetics has announced that it will acquire biotech company Cascadian Therapeutics for approximately $614 million.

Europe

Sanofi in talks to sell generics unit for €1.9bn

19 April 2018 France-based Sanofi has confirmed it is in negotiations to sell its European generics business Zentiva for €1.9 billion ($2.4 billion) to private equity firm Advent International.

Americas

Allele Biotech partners with Scientist.com to develop nanoantibodies